[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100469537":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":11,"studyPopulation":11,"armGroups":30,"interventions":43,"overallOfficials":11,"centralContacts":53,"locations":59,"responsibleParty":186,"collaborators":188,"id":191,"slug":11,"hasResults":192,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":11,"eligibilityCriteria":196,"healthyVolunteers":192,"sex":197,"minAge":198,"maxAge":11,"enrollmentInfo":199,"targetDuration":11,"studyType":202,"phases":203,"briefSummary":206,"conditions":207,"keywords":11,"overallStatus":62,"whyStopped":11,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},{"fullName":5,"class":6},"Qurient Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Number of participants with treatment-related adverse events as assessed by CTCAE v4.0",null,"28 days of cycle 1 (each cycle is 28 days)",[14,17,19,21],{"measure":15,"description":11,"timeFrame":16},"Change in the area under curve (AUC) of Q901","Cycle 1 Day 1 and Day 22, Cycle 2 Day 8 and Day 22 (each cycle is 28 days)",{"measure":18,"description":11,"timeFrame":16},"Change in the maximum plasma concentration (Cmax) of Q901",{"measure":20,"description":11,"timeFrame":16},"Change in the time of maximum plasma concentration (Tmax) of Q901",{"measure":22,"description":11,"timeFrame":23},"Tumor response using RECIST version 1.1 throughout study","Baseline and at the end of every even cycle up to approximately 2 years (each cycle is 28 days)",{"allocation":25,"interventionModel":26,"interventionModelDescription":11,"primaryPurpose":27,"observationalModel":11,"timePerspective":11,"maskingInfo":28},"NON_RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":29,"maskingDescription":11,"whoMasked":11},"NONE",[31,36,39],{"label":32,"type":33,"description":11,"interventionNames":34},"Dose escalation (Q901)","EXPERIMENTAL",[35],"Drug: Q901",{"label":37,"type":33,"description":11,"interventionNames":38},"Q901 Single-Agent Expansion Cohorts",[35],{"label":40,"type":33,"description":11,"interventionNames":41},"Q901 + KEYTRUDA® (pembrolizumab) Cohorts",[35,42],"Drug: KEYTRUDA® (pembrolizumab)",[44,49],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":11},"DRUG","Q901","The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter",[32,40,37],{"type":45,"name":50,"description":51,"armGroupLabels":52,"otherNames":11},"KEYTRUDA® (pembrolizumab)","KEYTRUDA® (pembrolizumab) will be administered Q6W",[40],[54],{"name":55,"role":56,"phone":57,"phoneExt":11,"email":58},"Qurient Clinical Trial Information","CONTACT","+82-31-8060-1610","clinicaltrial_info@qurient.com",[60,77,89,100,112,123,135,147,158,168,179],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Mayo Clinic","RECRUITING","Phoenix","Arizona","85054","United States","US",{"type":69,"coordinates":70},"Point",[71,72],-112.07404,33.44838,{"lat":72,"lon":71},[75],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},"See Central Contact",{"facility":78,"status":62,"city":79,"state":80,"zip":81,"country":66,"countryCode":67,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"University of Southern California","Los Angeles","California","90033",{"type":69,"coordinates":83},[84,85],-118.24368,34.05223,{"lat":85,"lon":84},[88],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},{"facility":61,"status":62,"city":90,"state":91,"zip":92,"country":66,"countryCode":67,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Jacksonville","Florida","32224",{"type":69,"coordinates":94},[95,96],-81.65565,30.33218,{"lat":96,"lon":95},[99],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},{"facility":101,"status":62,"city":102,"state":103,"zip":104,"country":66,"countryCode":67,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Northwestern University","Chicago","Illinois","60611",{"type":69,"coordinates":106},[107,108],-87.65005,41.85003,{"lat":108,"lon":107},[111],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},{"facility":61,"status":62,"city":113,"state":114,"zip":115,"country":66,"countryCode":67,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Rochester","Minnesota","55905",{"type":69,"coordinates":117},[118,119],-92.4699,44.02163,{"lat":119,"lon":118},[122],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},{"facility":124,"status":62,"city":125,"state":126,"zip":127,"country":66,"countryCode":67,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Atlantic Health System Hospital","Morristown","New Jersey","07960",{"type":69,"coordinates":129},[130,131],-74.48154,40.79677,{"lat":131,"lon":130},[134],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},{"facility":136,"status":62,"city":137,"state":138,"zip":139,"country":66,"countryCode":67,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Mary Crowley Cancer Research","Dallas","Texas","75230",{"type":69,"coordinates":141},[142,143],-96.80667,32.78306,{"lat":143,"lon":142},[146],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},{"facility":148,"status":62,"city":149,"state":11,"zip":11,"country":150,"countryCode":11,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"National Cancer Center","Goyang-si","South Korea",{"type":69,"coordinates":152},[153,154],126.835,37.65639,{"lat":154,"lon":153},[157],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},{"facility":159,"status":62,"city":160,"state":11,"zip":11,"country":150,"countryCode":11,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"CHA University Bundang Medical Center","Seongnam-si",{"type":69,"coordinates":162},[163,164],127.13778,37.43861,{"lat":164,"lon":163},[167],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},{"facility":169,"status":170,"city":171,"state":11,"zip":11,"country":150,"countryCode":11,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Asan Medical Center","NOT_YET_RECRUITING","Seoul",{"type":69,"coordinates":173},[174,175],126.9784,37.566,{"lat":175,"lon":174},[178],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},{"facility":180,"status":170,"city":171,"state":11,"zip":11,"country":150,"countryCode":11,"cosmosGeoPoint":181,"geoPoint":183,"contacts":184},"Severance Hospital",{"type":69,"coordinates":182},[174,175],{"lat":175,"lon":174},[185],{"name":76,"role":56,"phone":11,"phoneExt":11,"email":11},{"type":187,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[189],{"name":190,"class":6},"Merck Sharp & Dohme LLC","100469537",false,"NCT05394103","Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","A Phase 1\u002F2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose","Inclusion Criteria:\n\n* Participants with histologically or cytologically confirmed advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancer, who have progressed following standard-of-care therapy or for whom there is no standard therapy that confers clinical benefit\n* Measurable disease per RECIST v 1.1\n* ECOG performance status 0,1 or 2\n* Life expectancy of at least 3 months\n* Age ≥ 18 years\n* Signed, written IRB-approved informed consent form\n\nExclusion Criteria:\n\n* New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary\u002Fperipheral artery bypass graft, congestive heart failure within the past 6 months\n* Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of \\>470 msec (females) and \\>450 msec (males)\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy\n* Active, poorly controlled autoimmune or inflammatory diseases","ALL","18 Years",{"count":200,"type":201},130,"ESTIMATED","INTERVENTIONAL",[204,205],"PHASE1","PHASE2","Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab",[208,209],"Advanced Cancer","Metastatic Cancer","2025-08-13",{"date":212,"type":213},"2025-08-17","ACTUAL",{"date":215,"type":213},"2022-08-30",{"date":217,"type":201},"2026-08-30",{"name":5,"class":6},11]